Is Labcorp Holdings, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Labcorp Holdings, Inc. has moved from expensive to fair. Based on the current metrics, the company appears to be fairly valued. Key ratios include a P/E ratio of 28.86, an EV to EBITDA of 14.80, and a PEG ratio of 0.0. In comparison, peers in the Pharmaceuticals & Biotechnology industry exhibit varying valuations, with notable competitors having different P/E ratios that reflect their market positions.
In terms of performance, Labcorp has demonstrated strong returns, with a year-to-date return of 24.69% compared to the S&P 500's 13.30%, and a one-year return of 32.91% versus the S&P 500's 14.08%. This performance indicates that while Labcorp is fairly valued, it has outperformed the broader market over multiple periods, reinforcing its competitive position within the industry.